Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1993 2
1994 1
1995 2
1996 2
1997 2
1998 6
1999 5
2000 6
2001 5
2002 5
2003 7
2004 14
2005 10
2006 10
2007 8
2008 16
2009 12
2010 10
2011 10
2012 16
2013 13
2014 8
2015 9
2016 6
2017 8
2018 7
2019 4
2020 7
2021 9
2022 12
2023 8
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

220 results

Results by year

Filters applied: . Clear all
Page 1
Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis.
Tur C, Carbonell-Mirabent P, Cobo-Calvo Á, Otero-Romero S, Arrambide G, Midaglia L, Castilló J, Vidal-Jordana Á, Rodríguez-Acevedo B, Zabalza A, Galán I, Nos C, Salerno A, Auger C, Pareto D, Comabella M, Río J, Sastre-Garriga J, Rovira À, Tintoré M, Montalban X. Tur C, et al. Among authors: nos c. JAMA Neurol. 2023 Feb 1;80(2):151-160. doi: 10.1001/jamaneurol.2022.4655. JAMA Neurol. 2023. PMID: 36534392 Free PMC article.
[Lynch syndrome and endometrial cancer].
Bats AS, Rossi L, Le Frere-Belda MA, Narjoz C, Cournou C, Gosset M, Ngo C, Delomenie M, Nos C, Blons H, Laurent-Puig P, Lecuru F. Bats AS, et al. Among authors: nos c. Bull Cancer. 2017 Dec;104(12):1013-1021. doi: 10.1016/j.bulcan.2017.06.018. Epub 2017 Oct 21. Bull Cancer. 2017. PMID: 29061399 Review. French.
Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis.
Villacieros-Álvarez J, Espejo C, Arrambide G, Castillo M, Carbonell-Mirabent P, Rodriguez M, Bollo L, Castilló J, Comabella M, Galán I, Midaglia L, Mongay-Ochoa N, Nos C, Rio J, Rodríguez-Acevedo B, Sastre-Garriga J, Tur C, Vidal-Jordana A, Vilaseca A, Zabalza A, Auger C, Rovira A, Montalban X, Tintoré M, Cobo-Calvo Á. Villacieros-Álvarez J, et al. Among authors: nos c. Ann Neurol. 2023 Sep 14. doi: 10.1002/ana.26793. Online ahead of print. Ann Neurol. 2023. PMID: 37705507
Association of Very Early Treatment Initiation With the Risk of Long-term Disability in Patients With a First Demyelinating Event.
Cobo-Calvo A, Tur C, Otero-Romero S, Carbonell-Mirabent P, Ruiz M, Pappolla A, Villacieros Alvarez J, Vidal-Jordana A, Arrambide G, Castilló J, Galan I, Rodríguez Barranco M, Midaglia LS, Nos C, Rodriguez Acevedo B, Zabalza de Torres A, Mongay N, Rio J, Comabella M, Auger C, Sastre-Garriga J, Rovira A, Tintore M, Montalban X. Cobo-Calvo A, et al. Among authors: nos c. Neurology. 2023 Sep 26;101(13):e1280-e1292. doi: 10.1212/WNL.0000000000207664. Epub 2023 Jul 19. Neurology. 2023. PMID: 37468284 Free PMC article.
[Breast-conserving therapy of breast cancer].
Doridot V, Nos C, Aucouturier JS, Sigal-Zafrani B, Fourquet A, Clough KB. Doridot V, et al. Among authors: nos c. Cancer Radiother. 2004 Feb;8(1):21-8. doi: 10.1016/j.canrad.2003.10.008. Cancer Radiother. 2004. PMID: 15093197 Review. French.
ENSEMBLE PLUS: final results of shorter ocrelizumab infusion from a randomized controlled trial.
Hartung HP, Berger T, Bermel RA, Brochet B, Carroll WM, Holmøy T, Karabudak R, Killestein J, Nos C, Patti F, Perrin Ross A, Vanopdenbosch L, Vollmer T, Buffels R, Garas M, Kadner K, Manfrini M, Wang Q, Freedman MS. Hartung HP, et al. Among authors: nos c. J Neurol. 2024 Jul;271(7):4348-4360. doi: 10.1007/s00415-024-12326-z. Epub 2024 Apr 22. J Neurol. 2024. PMID: 38649522 Free PMC article. Clinical Trial.
A wearable device perspective on the standard definitions of disability progression in multiple sclerosis.
Dalla Costa G, Nos C, Zabalza A, Buron M, Magyari M, Sellebjerg F, Guerrero AI, Roselli L, La Porta ML, Martinis M, Bailon R, Kontaxis S, Laporta E, Garcia E, Pokorny FB, Schuller BW, Folarin A, Stewart C, Leocani L, Vairavan S, Cummins N, Dobson R, Hotopf M, Narayan V, Montalban X, Sorensen PS, Comi G. Dalla Costa G, et al. Among authors: nos c. Mult Scler. 2024 Jan;30(1):103-112. doi: 10.1177/13524585231214362. Epub 2023 Dec 12. Mult Scler. 2024. PMID: 38084497
Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTs.
Pappolla A, Auger C, Sao-Aviles A, Tur C, Rodriguez-Barranco M, Cobo-Calvo Á, Mongay-Ochoa N, Rodríguez-Acevedo B, Zabalza A, Midaglia L, Carbonell-Mirabent P, Carvajal R, Castilló-Justribó J, Braga N, Bollo L, Vidal-Jordana A, Arrambide G, Nos C, Salerno A, Galán I, Comabella M, Sastre-Garriga J, Tintoré M, Rovira A, Montalban X, Río J. Pappolla A, et al. Among authors: nos c. Mult Scler. 2024 Jun;30(7):820-832. doi: 10.1177/13524585241240653. Epub 2024 Mar 29. Mult Scler. 2024. PMID: 38551315
220 results